Alpha Tau Medical (Nasdaq: DRTS) wins DDW 2026 oral slot for Alpha DaRT pancreatic cancer trials

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. announced that clinical data from two Jerusalem trials of its Alpha DaRT® alpha-radiation therapy in pancreatic cancer have been accepted for a first-ever oral presentation at Digestive Disease Week (DDW) 2026.

The abstract, led by Principal Investigator Dr. Harold Jacob, will be presented on May 2, 2026 at 10:30am (Central) in the Pancreatic Cancer I: Diagnosis and Treatment session. The work underpins Alpha Tau’s broader clinical development, including its IMPACT pilot study in the U.S. and plans toward a future pivotal study.

Key Figures

DDW presentation date and time: May 2, 2026, 10:30am (Central) DDW 2026 conference dates: May 2–5, 2026 Company founding year: 2016

3 metrics

DDW presentation date and time May 2, 2026, 10:30am (Central) Pancreatic Cancer I: Diagnosis and Treatment session

DDW 2026 conference dates May 2–5, 2026 Digestive Disease Week 2026 schedule

Company founding year 2016 Alpha Tau Medical founded in Israel

Key Terms

Alpha DaRT, pancreatic adenocarcinoma, Digestive Disease Week (DDW), intratumoral delivery, +1 more

5 terms

Alpha DaRT medical

"Alpha Tau Medical Ltd. … developer of the innovative alpha-radiation cancer therapy Alpha DaRT®"

pancreatic adenocarcinoma medical

"a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma"

Pancreatic adenocarcinoma is a type of cancer that starts in the cells of the pancreas, the organ that helps digestion and controls blood sugar. It matters to investors because it is often aggressive and hard to detect early, so progress or setbacks in diagnostics, drugs or clinical trials can strongly affect the value of companies working on treatments—similar to how a breakthrough or failure in fixing a critical bridge can change the fortunes of contractors and insurers.

Digestive Disease Week (DDW) medical

"presenting results … has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026"

intratumoral delivery medical

"Alpha DaRT … is designed to enable … alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources"

A method of giving a medicine or therapeutic agent directly into a solid tumor, rather than into the bloodstream, to concentrate the treatment where cancer is located. Like putting a watering can on the plant instead of spraying the whole garden, it can increase local effectiveness and reduce side effects elsewhere in the body, which matters to investors because it can influence clinical success, safety profiles, regulatory approval chances and commercial value.

forward-looking statements regulatory

"This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-41316

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On March 31, 2026, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT^® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

The information in this Report on Form 6-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1 

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release dated March 31, 2026.

2 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Alpha Tau Medical Ltd.
Date: March 31, 2026	By:	/s/ Uzi Sofer
		Uzi Sofer
		Chief Executive Officer

3 

Exhibit 99.1

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT^® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

Jerusalem, March 31, 2026 - Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^® today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world’s premier international gastroenterology conference. This marks the first time that clinical results of Alpha DaRT in pancreatic cancer patients have been selected for presentation at a major gastroenterology conference.

The abstract, entitled “Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma,” has been selected for podium presentation in the Pancreatic Cancer I: Diagnosis and Treatment session on Saturday, May 2, 2026 at 10:30am (Central). The presentation will be led by study Principal Investigator Dr. Harold Jacob, Director of Advanced Gastrointestinal Endoscopy at Hadassah University Medical Center, and is based on combined data from two clinical protocols conducted at Hadassah Medical Center in Jerusalem, Israel.

“The acceptance of this abstract for an oral presentation at DDW is an important milestone for Alpha Tau” stated Uzi Sofer, CEO of Alpha Tau, “It reflects the growing recognition of the potential of our technology to address this devastating disease. With the vast majority of pancreatic cancer patients deemed inoperable at diagnosis, Alpha DaRT seeks to offer a truly novel approach for both locally advanced and metastatic patients, and we look forward to sharing these data at DDW.”

Dr. Harold Jacob, commented, “I am gratified that our work has been selected for an oral presentation at DDW. As the first clinical data of Alpha DaRT in pancreatic cancer to be presented at a major gastroenterology forum, this acceptance highlights the importance and potential of this technology. Alpha DaRT is designed to be uniquely suited for delivery by gastroenterologists via EUS, hopefully positioning our specialty at the forefront of a new era in pancreatic cancer therapy.”

Dr. Robert Den, Chief Medical Officer of Alpha Tau, commented, “The selection of this abstract for an oral presentation at DDW is a testament to the scientific rigor and clinical significance of the work conducted at Hadassah, and of course to Alpha Tau’s excellent investigational technology. These foundational studies have been instrumental in informing our clinical development program, including the IMPACT pilot study now actively enrolling in the U.S., as well as our ongoing work toward a future pivotal study. The full data will be presented at DDW in May.”

About DDW 2026

Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. DDW 2026 will be held May 2–5, 2026.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT^®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to the DDW presentation and Alpha DaRT treatment in pancreatic cancer patients, including the potential benefits, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on form 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

Investor Relations Contact:

IR@alphatau.com

FAQ

What did Alpha Tau Medical (DRTS) announce in this Form 6-K?

Alpha Tau Medical announced that clinical data from two Alpha DaRT pancreatic cancer trials in Jerusalem were accepted for an oral presentation at Digestive Disease Week (DDW) 2026, marking the first time its pancreatic cancer results will be showcased at a major gastroenterology conference.

When and where will Alpha Tau’s Alpha DaRT pancreatic cancer data be presented?

The Alpha DaRT pancreatic cancer data will be presented at Digestive Disease Week (DDW) 2026 on Saturday, May 2, 2026, at 10:30am (Central), during the Pancreatic Cancer I: Diagnosis and Treatment session, at the world’s premier international gastroenterology conference.

What clinical work underlies Alpha Tau’s DDW 2026 pancreatic cancer presentation?

The DDW 2026 presentation is based on combined data from two first-in-human feasibility, safety, and tumor control trials of Alpha DaRT in pancreatic adenocarcinoma, conducted at Hadassah Medical Center in Jerusalem under the direction of Principal Investigator Dr. Harold Jacob.

How does Alpha Tau describe the significance of the DDW 2026 oral presentation?

Alpha Tau’s CEO calls acceptance of the abstract an important milestone that reflects growing recognition of Alpha DaRT’s potential to address pancreatic cancer, especially for patients often deemed inoperable, and highlights the technology’s aim to offer a novel option for locally advanced and metastatic disease.

What ongoing and future studies does Alpha Tau link to the pancreatic cancer data?

Alpha Tau’s Chief Medical Officer notes that these foundational pancreatic cancer studies inform the company’s clinical development program, including the IMPACT pilot study now actively enrolling in the U.S., as well as ongoing work toward a future pivotal study of Alpha DaRT.

What is Alpha DaRT and how is it designed to treat solid tumors?

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) uses intratumoral radium-224 impregnated sources that release short-lived daughter atoms emitting high-energy alpha particles, aiming to destroy solid tumors while limiting radiation diffusion so surrounding healthy tissue is largely spared from high-dose exposure.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE DATED MARCH 31, 2026 11.4 KB